Dr. Christopher D Fletcher, MD
Claim this profileWilliam S Middleton VA Medical Center
Area of expertise
Lymphoma
Christopher D Fletcher, MD has run 3 trials for Lymphoma. Some of their research focus areas include:
Diffuse Large B-Cell Lymphoma
Christopher D Fletcher, MD has run 2 trials for Diffuse Large B-Cell Lymphoma. Some of their research focus areas include:
Affiliated Hospitals
William S Middleton VA Medical Center
University Of Wisconsin - Carbone Cancer Center
Clinical Trials Christopher D Fletcher, MD is currently running
Venetoclax + HMA
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.
Recruiting
1 award
Phase 2
7 criteria
Combination Therapy
for Multiple Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting
2 awards
Phase 3
32 criteria
More about Christopher D Fletcher, MD
Clinical Trial Related
6 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Christopher D Fletcher, MD has experience with
- Venetoclax
- Lenalidomide
- Azacitidine
- Blinatumomab
- Bortezomib
- Daratumumab And Hyaluronidase-fihj
Breakdown of trials Christopher D Fletcher, MD has run
Lymphoma
Diffuse Large B-Cell Lymphoma
Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Christopher D Fletcher, MD specialize in?
Christopher D Fletcher, MD focuses on Lymphoma and Diffuse Large B-Cell Lymphoma. In particular, much of their work with Lymphoma has involved Stage II patients, or patients who are Stage III.
Is Christopher D Fletcher, MD currently recruiting for clinical trials?
Yes, Christopher D Fletcher, MD is currently recruiting for 3 clinical trials in Madison Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Christopher D Fletcher, MD has studied deeply?
Yes, Christopher D Fletcher, MD has studied treatments such as Venetoclax, Lenalidomide, Azacitidine.
What is the best way to schedule an appointment with Christopher D Fletcher, MD?
Apply for one of the trials that Christopher D Fletcher, MD is conducting.
What is the office address of Christopher D Fletcher, MD?
The office of Christopher D Fletcher, MD is located at: William S Middleton VA Medical Center, Madison, Wisconsin 53705 United States. This is the address for their practice at the William S Middleton VA Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.